TDI-11861

TDI-11861 is a potent, small molecule inhibitor of soluble adenylyl cyclase (sAC, also known as ADCY10) being developed by Sacyl Pharmaceuticals as a non-hormonal, on-demand male contraceptive. The compound is characterized by a long off-rate, which enables sustained inhibition of sAC, a key enzyme required for sperm motility and the capacitation process necessary for fertilization. By reversibly impairing sperm function, TDI-11861 aims to provide a temporary window of infertility. In 2023, the molecule was used to achieve proof-of-concept for on-demand male contraception in preclinical models, demonstrating that a single dose could effectively prevent pregnancy in animal models.